Images
Participants
Contact
The “Corporación Catalana de Medios Audiovisuales” has published a report on the RiPCoN project, in which IRB Barcelona’s Structural Bioinformatics and Network Biology is participating. Headed by Patrick Aloy, this lab is conducting a computational study of the interactions between the coronavirus and human cells with the aim to identify drugs already on the market or under development that can tackle the spread of the virus. The goal is to identify an antiviral treatment and, in the long-term, a possible vaccine.
In addition, various media have reported on the efforts made by IRB Barcelona to conduct mass screening for the disease.
Link to: CCMA
Link to: CCMA
Link to: La Vanguardia
Link to: ABC
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
